Liver hepatokines and peroxisomes as therapeutic targets for cardiovascular diseases

Date
2020-10-22
Authors
Huang, Kerui
Bai, Hua
Major Professor
Advisor
Committee Member
Journal Title
Journal ISSN
Volume Title
Publisher
© 2021 Future Medicine Ltd
Altmetrics
Authors
Bai, Hua
Person
Research Projects
Organizational Units
Journal Issue
Series
Department
Genetics, Development and Cell Biology
Abstract
Increasing evidence from recent clinical studies indicates a close connection between liver dysfunction and cardiovascular diseases (CVDs) 1. Although it remains to be determined how patients with liver diseases often develop cardiovascular dysfunction, recent studies using animal models and epidemiology studies have shed light on the key role of hepatokines (a group of liver‐derived proteins) and hepatic peroxisome dysfunction in the induction of cardiomyopathy. Here, we summarize the role of representative hepatokines, Interleukin‐6 (IL‐6) and fetuin‐A, and liver peroxisome in the progression of cardiovascular diseases.
Comments
This is a manuscript of an editorial published as Huang, Kerui, and Hua Bai. "Liver hepatokines and peroxisomes as therapeutic targets for cardiovascular diseases." Future Cardiology 17, no. 4 (2020): 535-538. doi:10.2217/fca-2020-0166. Posted with permission.
Description
Keywords
Citation
DOI
Collections